Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer

This is a single site, open-label, single-arm phase II study to determine feasibility, tolerability, and preliminary efficacy of neoadjuvant ADG126 and pembrolizumab in stage II or III colorectal cancer.

Trial Details

NCT ID
NCT06846268
Phase
PHASE2
Sponsor
National University Hospital, Singapore
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • ADG126
  • Pembrolizumab
Locations (sample)
  • Singapore, Singapore|1.28967,103.85007

Key Eligibility Criteria

  • Willing and able to provide written informed consent for the trial.
  • Be ≥ 21 years of age on the date of signing informed consent.
  • ECOG performance status of 0 or 1.
  • Histologically confirmed colorectal adenocarcinoma. Rectal cancers allowed if the treatment plan was upfront surgery with no need for any neoadjuva…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →